176665-67-1

Basic information

• Product Name: 1,2-Ethanediamine, N,N,N'-trimethyl-N'-(4-nitrophenyl)-
• Synonyms: N,N,N'-trimethyl-N'- (4-nitrophenyl)-1,2-ethanediamine;N-(2-dimethylaminoethyl)-N-methyl-4-nitroaniline;N,N,N'-trimethyl-N'-(4-nitrophenyl)ethane-1,2-diamine;N,N,N'-trimethyl-N'-(4-nitrophenyl)-ethane-1,2-diamine;N1,N1,N2-trimethyl-N2-(4-nitrophenyl)ethane-1,2-diamine
• CAS NO: 176665-67-1
• Molecular Formula: C11H17N3O2
• Molecular Weight: 223.275
• Mol File: 176665-67-1.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 1,2-Ethanediamine, N,N,N'-trimethyl-N'-(4-nitrophenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2-Ethanediamine, N,N,N'-trimethyl-N'-(4-nitrophenyl)-(176665-67-1)
• EPA Substance Registry System: 1,2-Ethanediamine, N,N,N'-trimethyl-N'-(4-nitrophenyl)-(176665-67-1)

Safety Data

• Hazardous Substances Data: 176665-67-1(Hazardous Substances Data)

Usage

Derivative of

Ethanediamine (ethylenediamine)

Contains

Nitrophenyl group and three methyl groups attached to nitrogen atoms

Common uses

a. Reagent in organic synthesis
b. Building block in pharmaceuticals, agrochemicals, and fine chemicals production

Ability

Forms stable complexes with metal ions

Applications

a. Coordination chemistry
b. Catalysis
c. Development of dyes, pigments, and optoelectronic materials

Hazardous nature

Can cause irritation to skin, eyes, and respiratory system

Safety precautions

Handle with care due to potential hazards

Upstream product

• 104-79-0 N,N-diethyl-N'-methylethane-1,2-diamine 
• 350-46-9 4-Fluoronitrobenzene 
• 142-25-6 N,N',N'-trimethylenediamine 

Downstream Products

• 223785-93-1 N¹-(2-(dimethylamino)ethyl)-N¹-methylbenzene-1,4-diamine 
• 220224-39-5 N,N,N-trimethyl-2-[methyl (4-nitrophenyl)amino]-ethanaminium methylsulfate 

Relevant articles and documents

WEE1 inhibitors as well as preparation and application thereof

The invention relates to WEE1 inhibitors as well as preparation and application thereof. The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts, solvates, polymorphs or isomers thereof, and their use in the preparation of medicaments for the treatment of diseases associated with WEE1 activity.

CATIONIC NAPHTHYLDIAZO DYES AND AGENTS CONTAINING SAID DYES USED TO COLOUR KERATIN FIBRES

The invention relates to cationic naphthyldiazo dyes of general formula (I), and colouring agents containing said dyes, for colouring keratin fibres.

4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases

This invention is directed to aminothiazole compounds of formula (I) wherein R1 is a substituted or unsubstituted group selected from : C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; C1-6-alkoxyl; C1-6-alcohol; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; carbonyl; ether; (C1-6-alkyl)-carbonyl; (C1-6-alkyl)-aryl; (C1-6-alkyl)-cycloalkyl; (C1-6-alkyl)-(C1-6-alkoxyl); aryl-(C1-6-alkoxyl); thioether; thiol; and sulfonyl; wherein when R1 is substituted, each substituent independently is a halogen; haloalkyl; C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; hydroxyl; C1-6-alkoxyl; amino; nitro; thiol, thioether; imine; cyano; amido; phosphonato; phosphine; carboxyl; thiocarbonyl; sulfonyl; sulfonamide; ketone; aldehyde; ester; oxygen; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; or carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; and R2 is a carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, ring structure having a substituent at the position adjacent to the point of attachment, which ring structure is optionally further substituted, where each substituent of R2 independently is a halogen; haloalkyl; C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; hydroxyl; C1-6-alkoxyl; amino; nitro; thiol; thioether; imine; cyano; amido; phosphonato; phosphine; carboxyl; thiocarbonyl; sulfonyl; sulfonamide; ketone; aldehyde; ester; oxygen; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; or carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; or a pharmaceutically acceptable salt of a compound of formula (I), or a prodrug or pharmaceutically active metabolite of a compound of formula (I) or pharmaceutically acceptable salt thereof, for inhibiting cyclin-dependent kinases (CDKs), such as CDK1, CDK2, CDK4, and CDK6. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds and to methods of treating malignancies and other disorders by administering effective amounts of such compounds.